A Phase II trial Investigating PSA-IL2-GM-CSF-vaccine (ProscaVax) as a Front-Line Treatment in Patients with Early-Stage Prostate Cancer

Trial Profile

A Phase II trial Investigating PSA-IL2-GM-CSF-vaccine (ProscaVax) as a Front-Line Treatment in Patients with Early-Stage Prostate Cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2018 According to an OncBioMune Pharmaceuticals media release, the Company earlier this week completed and returned the revised study protocol based upon comments from the Scientific Review Committee (SRC) providing oversight on the trial.
    • 08 Mar 2018 According to an OncBioMune Pharmaceuticals media release, the company has selected Theradex as its contract research organization (CRO) for this and other planned phase 2 clinical trial (292849).
    • 31 Aug 2017 According to an OncBioMune Pharmaceuticals media release, the trial protocol of the study is now under review by the Regulatory Committee at Beth Israel Deaconess Medical Center/Harvard Medical School, the host hospital network for the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top